Walvax Biotechnology Co., Ltd.

8 clinical trials · Sponsor

Record	Firm	Date
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13 (NCT05934890)	Walvax Biotechnology Co., Ltd.	2023-11-23
A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 (NCT05394012)	Walvax Biotechnology Co., Ltd.	2022-12-01
A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 (NCT05396573)	Walvax Biotechnology Co., Ltd.	2022-07-01
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above (NCT04847102)	Walvax Biotechnology Co., Ltd.	2021-07-22
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years (NCT04450498)	Walvax Biotechnology Co., Ltd.	2020-12-23
Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population. (NCT04236960)	Walvax Biotechnology Co., Ltd.	2018-07-17

Every clearance here is in the API, with alerts when new ones post.